Wouter Meuleman
Life Science Investor
San Francisco Bay Area
Overview
Work Experience
Board Observer
2022 - Current
Precede Biosciences is breaking down the barriers to precision medicine by redefining what can be learned from a simple blood draw. By understanding the fundamental biology behind disease at any given moment, researchers and clinicians can better target medicines to the right patients in both drug development and clinical practice. Precede seeks to improve success rates for developers of new medicines and to be a part of building a future where every patient can receive a rapid, minimally invasive diagnosis and therapy that is precise to the biology of their disease.
Precede Biosciences is breaking down the barriers to precision medicine by redefining what can be gleaned from a simple blood draw.
Raised $57,000,000.00 from Illumina Ventures, OUP (Osage University Partners), Bristol-Myers Squibb, Lilly Asia Ventures, Qatar Investment Authority, Binney Street Capital and 5AM Ventures.
Partner
2020
Illumina Ventures pursues investments in early stage companies that are pioneering new applications of nucleic acid sequencing, developing products that will expand the genomics ecosystem, and utilizing genomics to improve human health.
Principal
2016 - 2020
Illumina Ventures visions is to improve human health by unlocking the power of the genome.
Board Member
2021
RedShiftBio has developed a proprietary life sciences platform combining its Microfluidic Modulation Spectroscopy (MMS) and expertise in high powered quantum cascade lasers that provides ultra-sensitive and ultra-precise measurements of molecular structure.
RedShift BioAnalytics is a developer and manufacturer of bioanalytical tools for the life science market.
Raised $65,749,688.00 from Technology Venture Partners, Waters Corporation and Illumina Ventures.
Board Member
2021
Lightcast Discovery is developing a flexible, accessible platform to accelerate single-cell, functional analysis at scale. Consolidating multiple, complex assays into intuitive streamlined workflows, the company is addressing key limitations in existing methods to provide the freedom to innovate and discover across a broad range of disciplines, from basic and translational research to drug discovery.
Board Member
2019
Fluent BioSciences, develops high sensitivity molecular analytical products that enables usage of extremely low molecular and cellular sample inputs.
Fluent Biosciences, a life science company, offering a molecular analysis of cells without the use of complex microfluidic instrumentation.
Raised $22,900,000.00 from National Institute of General Medical Science, National Institute of General Medical Science and Small Business Innovation Research.
Board Observer
2018
Ribometrix is a platform therapeutics company discovering small-molecule drugs that target functional RNA structures to create new avenues to treat human disease.
Board Observer
2019
Delfi Diagnostics detects cancer early, when it is most curable, using high precision non-invasive blood tests.
Raised $330,500,000.00 from PTX Capital, Northpond Ventures, OUP (Osage University Partners), Brown Advisory, Cowen Healthcare Investments, Foresite Capital, Point Field Partners, OrbiMed, Rock Springs Capital and T. Rowe Price.
Board Member
2015
Biota applies DNA sequencing and data science to explore the earth's subsurface. It offers DNA data services for production profiling, sweet spot identification, and reservoir connectivity.
Biota is pioneering biosurveillance across industrial sectors
Raised $1,433,559.00 from XSeed Capital and Illumina Ventures.
Board Observer
2017
DNA Script is focused on the manufacturing of synthetic DNA using a proprietary template-free enzymatic technology. This technology has the potential to greatly accelerate the development of new therapeutics, sustainable chemical production, improved crops as well as new applications such as data storage.
Director, Corporate and Business Development
2015 - 2019
Illumina, Inc. is a Life Sciences tools company developing, manufacturing and marketing integrated systems for the analysis of genetic variation and biological function.
Principal Scientist
2011 - 2014
Senior Staff Scientist
2010 - 2011
Staff Scientist
2009 - 2010
Illumina is an innovative technology and revolutionary assays aiming the analyze genetic variation and function.
Raised $1,278,000,000.00 from Bank of America.
Education
Master of Business Administration (MBA)
2008 - 2009
PhD
1998 - 2001
BSc/MSc
1992 - 1996
High School Diploma
1986 - 1992